Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HMGCR | P04035 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24436688 | 0.82 | HMGCR (0.45) | CYP3A4HMGCRHTTMAOBTUBB1 | |
| SCHEMBL28977384 | 0.77 | TUBB1 (0.39) | CYP3A4HTTTUBB1ACHEMAPT | |
| SCHEMBL21614377 | 0.77 | ESR1 (0.42) | CYP3A4HMGCRHTTMAOBTUBB1 | |
| SCHEMBL21614373 | 0.77 | HMGCR (0.41) | CYP3A4HMGCRHTTMAOBTUBB1 | |
| SCHEMBL21614371 | 0.77 | HMGCR (0.41) | CYP3A4HMGCRHTTMAOBTUBB1 | |
| SCHEMBL3623027 | 0.74 | ACHE (0.48) | CYP3A4HMGCRMAOBTUBB1ACHE | |
| SCHEMBL16071608 | 0.74 | ACHE (0.40) | CYP3A4HMGCRTUBB1ACHECA1 | |
| SCHEMBL25404759 | 0.73 | CYP3A4 (0.52) | CYP3A4HMGCRHTTMAOBFASN | |
| SCHEMBL12586769 | 0.73 | CYP3A4 (0.50) | CYP3A4HMGCRHTTMAOBFASN | |
| SCHEMBL21614374 | 0.72 | HMGCR (0.41) | CYP3A4HMGCRHTTMAOBTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | UNIVERSITE DE CAEN NORMANDIE (FR) | 2021-11-04 | — | — | US | disclosed |
| WO-2020007882-A1 | M-GUAIACOL DERIVATIVES, PREPARATION THEREOF, AND USES THEREOF | UNIVERSITE DE CAEN NORMANDIE (FR) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | MPG, MGLL, GANC | CYP3A4 700/4885HMGCR 852/4885HTT 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.